

Ontologies Classes Object Properties Data Properties Annotation Properties Individuals Datatypes Clouds

## Class: Stage\_1\_NSCLC

### Annotations (1)

- rdfs:comment** "If you have stage I NSCLC, surgery may be the only treatment you need. This may be done either by taking out the lobe of the lung that has the tumor (lobectomy) or by taking out a smaller piece of the lung (sleeve resection, segmentectomy, or wedge resection). At least some lymph nodes in the lung and in the space between the lungs will also be removed and checked for cancer. Segmentectomy or wedge resection is generally an option only for very small stage I cancers and for patients with other health problems that make removing the entire lobe dangerous. Still, most surgeons believe it is better to do a lobectomy if the patient can tolerate it, as it offers the best chance for cure. For people with stage I NSCLC that has a higher risk of coming back (based on size, location, or other factors), adjuvant chemotherapy (and possibly immunotherapy) after surgery may lower the risk that cancer will return. But doctors aren't always sure how to determine which people are likely to be helped by adjuvant treatment. New lab tests that look at the patterns of certain genes in the cancer cells may help with this. After surgery, the removed tissue is checked to see if there are cancer cells at the edges of the surgery specimen (called positive margins). This could mean that some cancer has been left behind, so a second surgery might be done to try to ensure that all the cancer has been removed. (This might be followed by chemotherapy as well.) Another option might be to use radiation therapy after surgery. For stage I cancers that are 4 centimeters across, another treatment option is immunotherapy with nivolumab along with chemotherapy before surgery. Additional therapy after surgery might be needed depending on what is found at the time of surgery. If you have serious health problems that prevent you from having surgery, you may get stereotactic body radiation therapy (SBRT) or another type of radiation therapy as your main treatment. Radiofrequency ablation (RFA) may be another option if the tumor is small and in the outer part of the lung."

### Superclasses (1)

- Non-Small\_Cell\_LC

### Disjoints (690)

'\Abraxane\_(Paclitaxel\_Albumin-stabilized\_Nanoparticle\_Formulation)\_\'', '\Afinitor\_(Everolimus)\_\'', '\Afinitor\_Disperz\_(Everolimus)\_\'', '\Alecensa\_(Alectinib)\_\'', '\Alimta\_(Pemetrexed\_Disodium)\_\'', '\Alunbrig\_(Brigatinib)\_\'', '\Alymsys\_(Bevacizumab)\_\'', '\Avastin\_(Bevacizumab)\_\'', '\Cyramza\_(Ramucirumab)\_\'', '\Enhertu\_(Fam-Trastuzumab\_Deruxtecan-nxki)\_\'', '\Etopophos\_(Etoposide\_Phosphate)\_\'', '\Exkivity\_(Mobocertinib\_Succinate)\_\'', '\Gavreto\_(Pralsetinib)\_\'', '\Gemzar\_(Gemcitabine\_Hydrochloride)\_\'', '\Gilotrif\_(Afatinib\_Dimaleate)\_\'', '\Hycamtin\_(Topotecan\_Hydrochloride)\_\'', '\Imfinzi\_(Durvalumab)\_\'', '\Imjudo\_(Tremelimumab-actl)\_\'', '\Infugem\_(Gemcitabine\_Hydrochloride)\_\'', '\Iressa\_(Gefitinib)\_\'', '\Keytruda\_(Pembrolizumab)\_\'', '\Krazati\_(Adagrasib)\_\'', '\Libtayo\_(Cemiplimab-rwlc)\_\'', '\Lorbrena\_(Lorlatinib)\_\'', '\Lumakras\_(Sotorasib)\_\'', '\Mekinist\_(Trametinib\_Dimethyl\_Sulfoxide)\_\'', '\Mvasi\_(Bevacizumab)\_\'', '\Opdivo\_(Nivolumab)\_\'', '\Portrazza\_(Necitumumab)\_\'', '\Retevmo\_(Selpercatinib)\_\'', '\Rozlytrek\_(Entrectinib)\_\'', '\Rybrevant\_(Amivantamab-vmjw)\_\'', '\Tabrecta\_(Capmatinib\_Hydrochloride)\_\'', '\Tafinlar\_(Dabrafenib\_Mesylate)\_\'', '\Tagrisso\_(Osimertinib\_Mesylate)\_\'', '\Taxotere\_(Docetaxel)\_\'', '\Tecentriq\_(Atezolizumab)\_\'', '\Tepmetko\_(Tepotinib\_Hydrochloride)\_\'', '\Trexall\_(Methotrexate\_Sodium)\_\'', '\Vizimpro\_(Dacomitinib)\_\'', '\Xalkori\_(Crizotinib)\_\'', '\Yervoy\_(Ipilimumab)\_\'', '\Zirabev\_(Bevacizumab)\_\'', '\Zykadia\_(Ceritinib)\_\'', 4A\_NSCLC, 4B\_NSCLC, Adagrasib\_, Adherence\_Based\_on\_Socioeconomics\_LC, Adherence\_Factors\_LC, Adverse\_Reactions\_ABRAX, Adverse\_Reactions\_ADAGR, Adverse\_Reactions\_AFATI, Adverse\_Reactions\_AFINI, Adverse\_Reactions\_AFINIT, Adverse\_Reactions\_ALECE, Adverse\_Reactions\_ALIMT, Adverse\_Reactions\_ALUNB, Adverse\_Reactions\_ARYMS, Adverse\_Reactions\_AMIVA, Adverse\_Reactions\_ATEZO, Adverse\_Reactions\_AVAST, Adverse\_Reactions\_BRIGA, Adverse\_Reactions\_CAPMA, Adverse\_Reactions\_CEMIP, Adverse\_Reactions\_CYRAM, Adverse\_Reactions\_DOXOR, Adverse\_Reactions\_DURVA, Adverse\_Reactions\_ENHER, Adverse\_Reactions\_ENTRE, Adverse\_Reactions\_ERLOT, Adverse\_Reactions\_ETOP, Adverse\_Reactions\_ETOPO, Adverse\_Reactions\_EXKIV, Adverse\_Reactions\_GAVRE, Adverse\_Reactions\_GEFIT, Adverse\_Reactions\_GEMZA, Adverse\_Reactions\_GILOT, Adverse\_Reactions\_HYCAM, Adverse\_Reactions\_IMFIN, Adverse\_Reactions\_IMJUD, Adverse\_Reactions\_INFUG, Adverse\_Reactions\_IRESS, Adverse\_Reactions\_KEYTR, Adverse\_Reactions\_KRAZA, Adverse\_Reactions\_LIBTA, Adverse\_Reactions\_LORBR, Adverse\_Reactions\_LUMAK, Adverse\_Reactions\_LURB, Adverse\_Reactions\_MEKIN, Adverse\_Reactions\_METH, Adverse\_Reactions\_MVASI, Adverse\_Reactions\_OPDIV, Adverse\_Reactions\_PORTR, Adverse\_Reactions\_RAMUC, Adverse\_Reactions\_RETEV, Adverse\_Reactions\_ROZLY,

Adverse\_Reactions\_RYBRE, Adverse\_Reactions\_SELPE, Adverse\_Reactions\_SOTOR, Adverse\_Reactions\_TABRE,  
 Adverse\_Reactions\_TAFIN, Adverse\_Reactions\_TAGRIS, Adverse\_Reactions\_TAXOT, Adverse\_Reactions\_TECEN,  
 Adverse\_Reactions\_TEPME, Adverse\_Reactions\_TOPO, Adverse\_Reactions\_TRAME, Adverse\_Reactions\_TREME,  
 Adverse\_Reactions\_TREXA, Adverse\_Reactions\_VINOR, Adverse\_Reactions\_VIZIM, Adverse\_Reactions\_XALKO,  
 Adverse\_Reactions\_YERVO, Adverse\_Reactions\_ZIRAB, Adverse\_Reactions\_ZYKAD, Afatinib\_Dimaleate\_, Age,  
 Air\_Pollution, Amivantamab-vmjw\_, Atezolizumab\_, Behavioral\_Factors\_LC, Beta\_Carotene\_Supplements\_LC,  
 Bio\_Sensors\_LC, Biological\_Effects\_LC, Breathalyzer\_LC, Breathing\_LC, Brigatinib\_,  
 Capmatinib\_Hydrochloride\_, Causes\_and\_Risks\_LC, Cemiplimab-rwlc\_, Chemical\_Sensors\_LC,  
 Choosing\_Quality\_of\_Life\_-\_Reasons\_People\_Forego\_Treatment, Choosing\_Survival\_-\_  
 Deciding\_to\_Undergo\_Treatment, Complications\_LC, Contraindications\_ABAX, Contraindications\_ADAGR,  
 Contraindications\_AFATI, Contraindications\_AFINI, Contraindications\_AFINIT, Contraindications\_ALECE,  
 Contraindications\_ALIMT, Contraindications\_ALUNB, Contraindications\_ARYMS, Contraindications\_AMIVA,  
 Contraindications\_ATEZO, Contraindications\_AVAST, Contraindications\_BRIGA, Contraindications\_CAPMA,  
 Contraindications\_CEMIP, Contraindications\_CYRAM, Contraindications\_DOXOR, Contraindications\_DURVA,  
 Contraindications\_ENHER, Contraindications\_ENTRE, Contraindications\_ERLOT, Contraindications\_ETOP,  
 Contraindications\_ETOPO, Contraindications\_EXKIV, Contraindications\_GAVRE, Contraindications\_GEFIT,  
 Contraindications\_GEMZA, Contraindications\_GILOT, Contraindications\_HYCAM, Contraindications\_IMFIN,  
 Contraindications\_IMJUD, Contraindications\_INFUG, Contraindications\_IRESS, Contraindications\_KEYTR,  
 Contraindications\_KRAZA, Contraindications\_LIBTA, Contraindications\_LORBR, Contraindications\_LUMAK,  
 Contraindications\_LURB, Contraindications\_MEKIN, Contraindications\_METH, Contraindications\_MVASI,  
 Contraindications\_OPDIV, Contraindications\_PORTR, Contraindications\_RAMUC, Contraindications\_RETEV,  
 Contraindications\_ROZLY, Contraindications\_RYBRE, Contraindications\_SELPE, Contraindications\_SOTOR,  
 Contraindications\_TABRE, Contraindications\_TAFIN, Contraindications\_TAGRIS, Contraindications\_TAXOT,  
 Contraindications\_TECEN, Contraindications\_TEPME, Contraindications\_TOPO, Contraindications\_TRAME,  
 Contraindications\_TREME, Contraindications\_TREXA, Contraindications\_VINOR, Contraindications\_VIZIM,  
 Contraindications\_XALKO, Contraindications\_YERVO, Contraindications\_ZIRAB, Contraindications\_ZYKAD,  
 Cultural\_Beliefs\_and\_Perceptions, Cultural\_LC, Degrees\_of\_Smoking\_LC, Demographic\_Factors\_LC, Diet\_LC,  
 Disparities\_in\_Incidence, Dosage\_and\_Administration\_ABAX, Dosage\_and\_Administration\_ADAGR,  
 Dosage\_and\_Administration\_AFATI, Dosage\_and\_Administration\_AFINI, Dosage\_and\_Administration\_AFINIT,  
 Dosage\_and\_Administration\_ALECE, Dosage\_and\_Administration\_ALIMT, Dosage\_and\_Administration\_ALUNB,  
 Dosage\_and\_Administration\_ARYMS, Dosage\_and\_Administration\_AMIVA, Dosage\_and\_Administration\_ATEZO,  
 Dosage\_and\_Administration\_AVAST, Dosage\_and\_Administration\_BRIGA, Dosage\_and\_Administration\_CAPMA,  
 Dosage\_and\_Administration\_CEMIP, Dosage\_and\_Administration\_CYRAM, Dosage\_and\_Administration\_DOXOR,  
 Dosage\_and\_Administration\_DURVA, Dosage\_and\_Administration\_ENHER, Dosage\_and\_Administration\_ENTRE,  
 Dosage\_and\_Administration\_ERLOT, Dosage\_and\_Administration\_ETOP, Dosage\_and\_Administration\_ETOPO,  
 Dosage\_and\_Administration\_EXKIV, Dosage\_and\_Administration\_GAVRE, Dosage\_and\_Administration\_GEFIT,  
 Dosage\_and\_Administration\_GEMZA, Dosage\_and\_Administration\_GILOT, Dosage\_and\_Administration\_HYCAM,  
 Dosage\_and\_Administration\_IMFIN, Dosage\_and\_Administration\_IMJUD, Dosage\_and\_Administration\_INFUG,  
 Dosage\_and\_Administration\_IRESS, Dosage\_and\_Administration\_KEYTR, Dosage\_and\_Administration\_KRAZA,  
 Dosage\_and\_Administration\_LIBTA, Dosage\_and\_Administration\_LORBR, Dosage\_and\_Administration\_LUMAK,  
 Dosage\_and\_Administration\_LURB, Dosage\_and\_Administration\_MEKIN, Dosage\_and\_Administration\_METH,  
 Dosage\_and\_Administration\_MVASI, Dosage\_and\_Administration\_OPDIV, Dosage\_and\_Administration\_PORTR,  
 Dosage\_and\_Administration\_RAMUC, Dosage\_and\_Administration\_RETEV, Dosage\_and\_Administration\_ROZLY,  
 Dosage\_and\_Administration\_RYBRE, Dosage\_and\_Administration\_SELPE, Dosage\_and\_Administration\_SOTOR,  
 Dosage\_and\_Administration\_TABRE, Dosage\_and\_Administration\_TAFIN, Dosage\_and\_Administration\_TAGRIS,  
 Dosage\_and\_Administration\_TAXOT, Dosage\_and\_Administration\_TECEN, Dosage\_and\_Administration\_TEPME,  
 Dosage\_and\_Administration\_TOPO, Dosage\_and\_Administration\_TRAME, Dosage\_and\_Administration\_TREME,  
 Dosage\_and\_Administration\_TREXA, Dosage\_and\_Administration\_VINOR, Dosage\_and\_Administration\_VIZIM,  
 Dosage\_and\_Administration\_XALKO, Dosage\_and\_Administration\_YERVO, Dosage\_and\_Administration\_ZIRAB,  
 Dosage\_and\_Administration\_ZYKAD, Dosage\_Forms\_and\_Strengths\_ABAX,  
 Dosage\_Forms\_and\_Strengths\_ADAGR, Dosage\_Forms\_and\_Strengths\_AFATI,  
 Dosage\_Forms\_and\_Strengths\_AFINI, Dosage\_Forms\_and\_Strengths\_AFINIT,  
 Dosage\_Forms\_and\_Strengths\_ALECE, Dosage\_Forms\_and\_Strengths\_ALIMT,  
 Dosage\_Forms\_and\_Strengths\_ALUNB, Dosage\_Forms\_and\_Strengths\_ARYMS,  
 Dosage\_Forms\_and\_Strengths\_AMIVA, Dosage\_Forms\_and\_Strengths\_ATEZO,  
 Dosage\_Forms\_and\_Strengths\_AVAST, Dosage\_Forms\_and\_Strengths\_BRIGA,  
 Dosage\_Forms\_and\_Strengths\_CAPMA, Dosage\_Forms\_and\_Strengths\_CEMIP,  
 Dosage\_Forms\_and\_Strengths\_CYRAM, Dosage\_Forms\_and\_Strengths\_DOXOR,  
 Dosage\_Forms\_and\_Strengths\_DURVA, Dosage\_Forms\_and\_Strengths\_ENHER,  
 Dosage\_Forms\_and\_Strengths\_ENTRE, Dosage\_Forms\_and\_Strengths\_ERLOT,  
 Dosage\_Forms\_and\_Strengths\_ETOP, Dosage\_Forms\_and\_Strengths\_ETOPO,  
 Dosage\_Forms\_and\_Strengths\_EXKIV, Dosage\_Forms\_and\_Strengths\_GAVRE,  
 Dosage\_Forms\_and\_Strengths\_GEFIT, Dosage\_Forms\_and\_Strengths\_GEMZA,  
 Dosage\_Forms\_and\_Strengths\_GILOT, Dosage\_Forms\_and\_Strengths\_HYCAM,  
 Dosage\_Forms\_and\_Strengths\_IMFIN, Dosage\_Forms\_and\_Strengths\_IMJUD,

Dosage\_Forms\_and\_Strengths\_INFUG, Dosage\_Forms\_and\_Strengths\_IRESS,  
 Dosage\_Forms\_and\_Strengths\_KEYTR, Dosage\_Forms\_and\_Strengths\_KRAZA,  
 Dosage\_Forms\_and\_Strengths\_LIBTA, Dosage\_Forms\_and\_Strengths\_LORBR,  
 Dosage\_Forms\_and\_Strengths\_LUMAK, Dosage\_Forms\_and\_Strengths\_LURB,  
 Dosage\_Forms\_and\_Strengths\_MEKIN, Dosage\_Forms\_and\_Strengths\_METH,  
 Dosage\_Forms\_and\_Strengths\_MVASI, Dosage\_Forms\_and\_Strengths\_OPDIV,  
 Dosage\_Forms\_and\_Strengths\_PORTR, Dosage\_Forms\_and\_Strengths\_RAMUC,  
 Dosage\_Forms\_and\_Strengths\_RETEV, Dosage\_Forms\_and\_Strengths\_ROZLY,  
 Dosage\_Forms\_and\_Strengths\_RYBRE, Dosage\_Forms\_and\_Strengths\_SELPE,  
 Dosage\_Forms\_and\_Strengths\_SOTOR, Dosage\_Forms\_and\_Strengths\_TABRE,  
 Dosage\_Forms\_and\_Strengths\_TAFIN, Dosage\_Forms\_and\_Strengths\_TAGRIS,  
 Dosage\_Forms\_and\_Strengths\_TAXOT, Dosage\_Forms\_and\_Strengths\_TECEN,  
 Dosage\_Forms\_and\_Strengths\_TEPME, Dosage\_Forms\_and\_Strengths\_TOPO,  
 Dosage\_Forms\_and\_Strengths\_TRAME, Dosage\_Forms\_and\_Strengths\_TREME,  
 Dosage\_Forms\_and\_Strengths\_TREXA, Dosage\_Forms\_and\_Strengths\_VINOR,  
 Dosage\_Forms\_and\_Strengths\_VIZIM, Dosage\_Forms\_and\_Strengths\_XALKO,  
 Dosage\_Forms\_and\_Strengths\_YERVO, Dosage\_Forms\_and\_Strengths\_ZIRAB,  
 Dosage\_Forms\_and\_Strengths\_ZYKAD, Doxorubicin\_Hydrochloride\_, Drug\_Interactions\_ABRAX,  
 Drug\_Interactions\_ADAGR, Drug\_Interactions\_AFATI, Drug\_Interactions\_AFINI, Drug\_Interactions\_AFINIT,  
 Drug\_Interactions\_ALECE, Drug\_Interactions\_ALIMT, Drug\_Interactions\_ALUNB, Drug\_Interactions\_ALYMS,  
 Drug\_Interactions\_AMIVA, Drug\_Interactions\_ATEZO, Drug\_Interactions\_AVAST, Drug\_Interactions\_BRIGA,  
 Drug\_Interactions\_CAPMA, Drug\_Interactions\_CEMIP, Drug\_Interactions\_CYRAM, Drug\_Interactions\_DOXOR,  
 Drug\_Interactions\_DURVA, Drug\_Interactions\_ENHER, Drug\_Interactions\_ENTRE, Drug\_Interactions\_ERLOT,  
 Drug\_Interactions\_ETOP, Drug\_Interactions\_ETOPO, Drug\_Interactions\_EXKIV, Drug\_Interactions\_GAVRE,  
 Drug\_Interactions\_GEFIT, Drug\_Interactions\_GEMZA, Drug\_Interactions\_GILOT, Drug\_Interactions\_HYCAM,  
 Drug\_Interactions\_IMFIN, Drug\_Interactions\_IMJUD, Drug\_Interactions\_INFUG, Drug\_Interactions\_IRESS,  
 Drug\_Interactions\_KEYTR, Drug\_Interactions\_KRAZA, Drug\_Interactions\_LIBTA, Drug\_Interactions\_LORBR,  
 Drug\_Interactions\_LUMAK, Drug\_Interactions\_LURB, Drug\_Interactions\_MEKIN, Drug\_Interactions\_METH,  
 Drug\_Interactions\_MVASI, Drug\_Interactions\_OPDIV, Drug\_Interactions\_PORTR, Drug\_Interactions\_RAMUC,  
 Drug\_Interactions\_RETEV, Drug\_Interactions\_ROZLY, Drug\_Interactions\_RYBRE, Drug\_Interactions\_SELPE,  
 Drug\_Interactions\_SOTOR, Drug\_Interactions\_TABRE, Drug\_Interactions\_TAFIN, Drug\_Interactions\_TAGRIS,  
 Drug\_Interactions\_TAXOT, Drug\_Interactions\_TECEN, Drug\_Interactions\_TEPME, Drug\_Interactions\_TOPO,  
 Drug\_Interactions\_TRAME, Drug\_Interactions\_TREME, Drug\_Interactions\_TREXA, Drug\_Interactions\_VINOR,  
 Drug\_Interactions\_VIZIM, Drug\_Interactions\_XALKO, Drug\_Interactions\_YERVO, Drug\_Interactions\_ZIRAB,  
 Drug\_Interactions\_ZYKAD, Durvalumab\_, E-Cigarettes\_LC, Electronic\_Sensors\_LC, Emotions\_LC,  
 End\_of\_Life\_Decisions, Entrectinib\_, Environmental\_Factors\_LC, Enzymatic\_Sensors\_LC,  
 Erlotinib\_Hydrochloride\_, Etoposide\_, Exercise\_LC, Extensive\_Stage\_SCLC, Family\_History\_LC, Gefitinib\_,  
 Genomic\_Sequencing\_LC, Geographical\_Location, Habits\_LC, HIV\_Infection\_LC, Immunosensors\_LC,  
 Increased\_Susceptibility\_LC, Indications\_and\_Usage\_ABRAX, Indications\_and\_Usage\_ADAGR,  
 Indications\_and\_Usage\_AFATI, Indications\_and\_Usage\_AFINI, Indications\_and\_Usage\_AFINIT,  
 Indications\_and\_Usage\_ALECE, Indications\_and\_Usage\_ALIMT, Indications\_and\_Usage\_ALUNB,  
 Indications\_and\_Usage\_ALYMS, Indications\_and\_Usage\_AMIVA, Indications\_and\_Usage\_ATEZO,  
 Indications\_and\_Usage\_AVAST, Indications\_and\_Usage\_BRIGA, Indications\_and\_Usage\_CAPMA,  
 Indications\_and\_Usage\_CEMIP, Indications\_and\_Usage\_CYRAM, Indications\_and\_Usage\_DOXOR,  
 Indications\_and\_Usage\_DURVA, Indications\_and\_Usage\_ENHER, Indications\_and\_Usage\_ENTRE,  
 Indications\_and\_Usage\_ERLOT, Indications\_and\_Usage\_ETOP, Indications\_and\_Usage\_ETOPO,  
 Indications\_and\_Usage\_EXKIV, Indications\_and\_Usage\_GAVRE, Indications\_and\_Usage\_GEFIT,  
 Indications\_and\_Usage\_GEMZA, Indications\_and\_Usage\_GILOT, Indications\_and\_Usage\_HYCAM,  
 Indications\_and\_Usage\_IMFIN, Indications\_and\_Usage\_IMJUD, Indications\_and\_Usage\_INFUG,  
 Indications\_and\_Usage\_IRESS, Indications\_and\_Usage\_KEYTR, Indications\_and\_Usage\_KRAZA,  
 Indications\_and\_Usage\_LIBTA, Indications\_and\_Usage\_LORBR, Indications\_and\_Usage\_LUMAK,  
 Indications\_and\_Usage\_LURB, Indications\_and\_Usage\_MEKIN, Indications\_and\_Usage\_METH,  
 Indications\_and\_Usage\_MVASI, Indications\_and\_Usage\_OPDIV, Indications\_and\_Usage\_PORTR,  
 Indications\_and\_Usage\_RAMUC, Indications\_and\_Usage\_RETEV, Indications\_and\_Usage\_ROZLY,  
 Indications\_and\_Usage\_RYBRE, Indications\_and\_Usage\_SELPE, Indications\_and\_Usage\_SOTOR,  
 Indications\_and\_Usage\_TABRE, Indications\_and\_Usage\_TAFIN, Indications\_and\_Usage\_TAGRIS,  
 Indications\_and\_Usage\_TAXOT, Indications\_and\_Usage\_TECEN, Indications\_and\_Usage\_TEPME,  
 Indications\_and\_Usage\_TOPO, Indications\_and\_Usage\_TRAME, Indications\_and\_Usage\_TREME,  
 Indications\_and\_Usage\_TREXA, Indications\_and\_Usage\_VINOR, Indications\_and\_Usage\_VIZIM,  
 Indications\_and\_Usage\_XALKO, Indications\_and\_Usage\_YERVO, Indications\_and\_Usage\_ZIRAB,  
 Indications\_and\_Usage\_ZYKAD, Limited\_Stage\_SCLC, Living\_with\_LC\_LC, Location\_LC, Lurbinectedin\_,  
 Marijuana\_Smoking\_LC, Medications\_LC, Methotrexate\_Sodium\_, Never-Smokers\_LC, Non-  
 Small\_Cell\_LC\_NSCLC, Non-Small\_Cell\_Lung\_Cancer, Non-Small\_Cell\_Medication\_LC\_, Non-Smokers\_LC, Non-  
 Smokers\_NSCLC, Non-Smokers\_SCLC, Nutrition\_LC, Occupational\_Exposure,  
 Physical\_Activity\_For\_Mitigation\_of\_LC, Physical\_Activity\_For\_Prevention\_Of\_LC, Preventative\_habits\_LC,

Quitting/Not\_Smoking\_LC, Racial/Ethnic, Radiation\_Exposure\_LC, Ramucirumab\_, Recurring\_LC\_NSCLC, Recurring\_LC\_SCLC, Rural\_LC, Second-hand\_Smoke\_LC, Secondhand\_Smoke\_LC, Selpercatinib\_, Sensor\_Factors\_LC, Size\_of\_the\_community\_LC, Sleep\_LC, Small\_Cell\_LC, Small\_Cell\_LC\_SCLC, Small\_Cell\_Lung\_Cancer, Small\_Cell\_Medication\_LC\_, Smoke\_LC, Smokers\_LC, Smokers\_NSCLC, Smokers\_SCLC, Smoking\_LC, Smoking\_Marijuana\_LC, Smoking\_Other\_Drugs\_LC, Smoking\_Tobacco\_LC, Socioeconomics\_LC, Sotorasib\_, Stage\_0\_NSCLC, **Stage\_1\_NSCLC**, Stage\_1\_SCLC, Stage\_2\_NSCLC, Stage\_3A\_NSCLC, Stage\_3B\_NSCLC, Stage\_4\_NSCLC, Support\_Groups\_LC, Symptoms\_and\_Tests\_LC, Symptoms\_NSC, Symptoms\_SC, Tests\_NSC, Tests\_SC, Tobacco\_Smoking, Tobacco\_Smoking\_LC, Topotecan\_Hydrochloride\_, Tramentinib\_Dimethyl\_Sulfoxide, Treatment\_Regimens\_LC, Tremelimumab-actl\_, Urban\_LC, Use\_in\_Specific\_Populations\_ABRAX, Use\_in\_Specific\_Populations\_ADAGR, Use\_in\_Specific\_Populations\_AFATI, Use\_in\_Specific\_Populations\_AFINI, Use\_in\_Specific\_Populations\_AFINIT, Use\_in\_Specific\_Populations\_ALECE, Use\_in\_Specific\_Populations\_ALIMT, Use\_in\_Specific\_Populations\_ALUNB, Use\_in\_Specific\_Populations\_ARYMS, Use\_in\_Specific\_Populations\_AMIVA, Use\_in\_Specific\_Populations\_ATEZO, Use\_in\_Specific\_Populations\_AVAST, Use\_in\_Specific\_Populations\_BRIGA, Use\_in\_Specific\_Populations\_CAPMA, Use\_in\_Specific\_Populations\_CEMIP, Use\_in\_Specific\_Populations\_CYRAM, Use\_in\_Specific\_Populations\_DOXOR, Use\_in\_Specific\_Populations\_DURVA, Use\_in\_Specific\_Populations\_ENHER, Use\_in\_Specific\_Populations\_ENTRE, Use\_in\_Specific\_Populations\_ERLOT, Use\_in\_Specific\_Populations\_ETOP, Use\_in\_Specific\_Populations\_ETOPO, Use\_in\_Specific\_Populations\_EXKIV, Use\_in\_Specific\_Populations\_GAVRE, Use\_in\_Specific\_Populations\_GEFIT, Use\_in\_Specific\_Populations\_GEMZA, Use\_in\_Specific\_Populations\_GILOT, Use\_in\_Specific\_Populations\_HYCAM, Use\_in\_Specific\_Populations\_IMFIN, Use\_in\_Specific\_Populations\_IMJUD, Use\_in\_Specific\_Populations\_INFUG, Use\_in\_Specific\_Populations\_IRESS, Use\_in\_Specific\_Populations\_KEYTR, Use\_in\_Specific\_Populations\_KRAZA, Use\_in\_Specific\_Populations\_LIBTA, Use\_in\_Specific\_Populations\_LORBR, Use\_in\_Specific\_Populations\_LUMAK, Use\_in\_Specific\_Populations\_LURB, Use\_in\_Specific\_Populations\_MEKIN, Use\_in\_Specific\_Populations\_METH, Use\_in\_Specific\_Populations\_MVASI, Use\_in\_Specific\_Populations\_OPDIV, Use\_in\_Specific\_Populations\_PORTR, Use\_in\_Specific\_Populations\_RAMUC, Use\_in\_Specific\_Populations\_RETEV, Use\_in\_Specific\_Populations\_ROZLY, Use\_in\_Specific\_Populations\_RYBRE, Use\_in\_Specific\_Populations\_SELPE, Use\_in\_Specific\_Populations\_SOTOR, Use\_in\_Specific\_Populations\_TABRE, Use\_in\_Specific\_Populations\_TAFIN, Use\_in\_Specific\_Populations\_TAGRIS, Use\_in\_Specific\_Populations\_TAXOT, Use\_in\_Specific\_Populations\_TECEN, Use\_in\_Specific\_Populations\_TEPME, Use\_in\_Specific\_Populations\_TOPO, Use\_in\_Specific\_Populations\_TRAME, Use\_in\_Specific\_Populations\_TREME, Use\_in\_Specific\_Populations\_TREXA, Use\_in\_Specific\_Populations\_VINOR, Use\_in\_Specific\_Populations\_VIZIM, Use\_in\_Specific\_Populations\_XALKO, Use\_in\_Specific\_Populations\_YERVO, Use\_in\_Specific\_Populations\_ZIRAB, Use\_in\_Specific\_Populations\_ZYKAD, Vinorelbine\_Tartrate\_, Warnings\_and\_Precautions\_ABRAX, Warnings\_and\_Precautions\_ADAGR, Warnings\_and\_Precautions\_AFATI, Warnings\_and\_Precautions\_AFINI, Warnings\_and\_Precautions\_AFINIT, Warnings\_and\_Precautions\_ALECE, Warnings\_and\_Precautions\_ALIMT, Warnings\_and\_Precautions\_ALUNB, Warnings\_and\_Precautions\_ARYMS, Warnings\_and\_Precautions\_AMIVA, Warnings\_and\_Precautions\_ATEZO, Warnings\_and\_Precautions\_AVAST, Warnings\_and\_Precautions\_BRIGA, Warnings\_and\_Precautions\_CAPMA, Warnings\_and\_Precautions\_CEMIP, Warnings\_and\_Precautions\_CYRAM, Warnings\_and\_Precautions\_DOXOR, Warnings\_and\_Precautions\_DURVA, Warnings\_and\_Precautions\_ENHER, Warnings\_and\_Precautions\_ENTRE, Warnings\_and\_Precautions\_ERLOT, Warnings\_and\_Precautions\_ETOP, Warnings\_and\_Precautions\_ETOPO, Warnings\_and\_Precautions\_EXKIV, Warnings\_and\_Precautions\_GAVRE, Warnings\_and\_Precautions\_GEFIT, Warnings\_and\_Precautions\_GEMZA, Warnings\_and\_Precautions\_GILOT, Warnings\_and\_Precautions\_HYCAM, Warnings\_and\_Precautions\_IMFIN, Warnings\_and\_Precautions\_IMJUD, Warnings\_and\_Precautions\_INFUG, Warnings\_and\_Precautions\_IRESS, Warnings\_and\_Precautions\_KEYTR, Warnings\_and\_Precautions\_KRAZA, Warnings\_and\_Precautions\_LIBTA, Warnings\_and\_Precautions\_LORBR, Warnings\_and\_Precautions\_LUMAK, Warnings\_and\_Precautions\_LURB, Warnings\_and\_Precautions\_MEKIN, Warnings\_and\_Precautions\_METH, Warnings\_and\_Precautions\_MVASI, Warnings\_and\_Precautions\_OPDIV, Warnings\_and\_Precautions\_PORTR, Warnings\_and\_Precautions\_RAMUC, Warnings\_and\_Precautions\_RETEV, Warnings\_and\_Precautions\_ROZLY, Warnings\_and\_Precautions\_RYBRE, Warnings\_and\_Precautions\_SELPE, Warnings\_and\_Precautions\_SOTOR, Warnings\_and\_Precautions\_TABRE, Warnings\_and\_Precautions\_TAFIN, Warnings\_and\_Precautions\_TAGRIS, Warnings\_and\_Precautions\_TAXOT, Warnings\_and\_Precautions\_TECEN, Warnings\_and\_Precautions\_TEPME, Warnings\_and\_Precautions\_TOPO, Warnings\_and\_Precautions\_TRAME, Warnings\_and\_Precautions\_TREME, Warnings\_and\_Precautions\_TREXA, Warnings\_and\_Precautions\_VINOR, Warnings\_and\_Precautions\_VIZIM, Warnings\_and\_Precautions\_XALKO, Warnings\_and\_Precautions\_YERVO, Warnings\_and\_Precautions\_ZIRAB, Warnings\_and\_Precautions\_ZYKAD

OWL HTML inside